rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    INBX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Inhibrx Biosciences Analyst Cuts Price Target Despite Data Catalysts In 2027
      Nov 16BenzingaINBX
      Inhibrx Biosciences earnings on deck as losses expected to narrow
      Nov 12Investing.comINBX
      Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price
      Oct 23Yahoo FinanceINBX
      Inhibrx CEO Mark Lappe buys over $848k in company stock
      Oct 14Investing.comINBX
      Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?

      Inhibrx Biosciences recently announced that it will present updated data on its clinical-stage candidates INBRX-106 and INBRX-109 from phase 2/3 and phase 2 studies in head and neck squamous cell carcinoma and conventional chondrosarcoma at major oncology and tumor society conferences in Europe, the US, and South Korea. This cluster of high-profile scientific presentations, with materials to be shared on the company’s investor website, highlights how Inhibrx is bringing its clinical data...

      Oct 14Yahoo FinanceINBX
      Inhibrx Announces Participation in Upcoming Scientific Conferences
      Oct 13Yahoo FinanceINBX
      Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

      Inhibrx Biosciences' CEO bought $3.6 million in shares after strong Phase 2 data, as insiders accumulate stock amid heavy short interest and an upcoming FDA decision on ozekibart.

      Oct 2Yahoo FinanceINBX
      Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating

      Inhibrx Biosciences (INBX) has drawn investor attention after a sharp move in the share price. The US$101.71 close now sits alongside a year-to-date gain of about 35%. Recent trading has been choppy, with a 1-day share price return of 2.11% following a 7-day share price return that fell 9.22% and a 30-day share price return down 17.58%. Despite this, Inhibrx Biosciences still shows a year-to-date share price return of 35.54% and a very large 1-year total shareholder return of 214.79%. This...

      Sep 29Yahoo FinanceINBX
      Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock
      Sep 28Investing.comINBX
      Inhibrx Biosciences Insider Bought Shares Worth $998,784, According to a Recent SEC Filing

      Mark Lappe, Director, Chief Executive Officer, on September 25, 2026, executed a purchase for 10,000

      Sep 28Yahoo FinanceINBX
      Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?

      Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention. Its experimental cancer drug INBRX-106, combined with Merck’s Keytruda, produced a confirmed response rate nearly twice that of Keytruda alone in a Phase 2 head and neck cancer study. The results were even stronger among a […]

      Sep 24Yahoo FinanceINBX
      Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock
      Sep 23Investing.comINBX
      Citizens reiterates Market Perform on Inhibrx Biosciences stock
      Sep 18Investing.comINBX
      Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock
      Sep 17Investing.comINBX
      Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing

      Jon Faiz Kayyem, Director, on September 16, 2026, executed a purchase for 5,000 shares in Inhibrx Bi

      Sep 17Yahoo FinanceINBX
      Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors? | The Motley Fool

      Lappe's purchase through family trusts boosts his beneficial ownership to 950,000 shares, or 6% of outstanding equity, as Inhibrx trades near $114 following a 293% gain over the past year.

      Sep 16The Motley FoolINBX
      Inhibrx director Kimberly Manhard sells $163,542 in company stock
      Sep 15Investing.comINBX
      Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?

      Motley Fool Press Release.

      Sep 15The Globe and MailINBX
      Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
      Sep 14Seeking AlphaINBX
      Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock
      Sep 11Investing.comINBX
      Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL)

      Detailed price information for Circle Internet Group Cl A (CRCL-N) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailINBX
      Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ)
      Sep 9Seeking AlphaINBX
      H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy
      Sep 9Investing.comINBX
      Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom (NASDAQ:INBX)
      Sep 9Seeking AlphaINBX
      Inhibrx director Jon Kayyem buys $567,580 in company stock
      Sep 9Investing.comINBX
      Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
      Sep 8BenzingaINBX
      Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
      Sep 8Seeking AlphaINBXMRK
      Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data

      Inhibrx Biosciences (NASDAQ:INBX) shares gained 6% on Tuesday after the biotechnology company reported encouraging Phase 2 results for INBRX-106 in combination with pembrolizumab in patients with head and neck cancer. Data from the HexAgon study showed a confirmed objective response rate of 48.

      Sep 8Yahoo FinanceINBX
      Inhibrx stock jumps on positive cancer drug trial results
      Sep 8Investing.comINBX
      Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
      Sep 8ReutersINBX
      Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

      Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced that it will host a live webcast presentation on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time, to provide primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 a

      Sep 4Yahoo FinanceINBX
      Citizens reiterates Market Perform on Inhibrx Biosciences stock
      Aug 27Investing.comINBX
      Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target
      Aug 21Investing.comINBXSF

      This is the newest page. Registered accounts read further back.